|By Marketwired .||
|January 7, 2014 08:30 AM EST|
CARLSBAD, CA -- (Marketwired) -- 01/07/14 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw, will present a corporate overview of ISCO and its subsidiaries at the Biotech Showcase 2014 on Monday, January 13th at 9:30 a.m. PST. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel.
Biotech Showcase 2014 conference presentation details:
Date: Monday, January 13, 2014
Time: 9:30 a.m. PST
Location: Parc 55 Wyndham Union Square Hotel, San Francisco, CA
Room: Room Mission II - Track C
Conference details: http://www.ebdgroup.com/bts/index.php
Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team. To register for the event, please visit the conference website at www.ebdgroup.com/bts/registration/index.php.
Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year. For more information, please visit the conference website at http://www.ebdgroup.com/bts/index.php
ISCO's lead indication is Parkinson's disease. The Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Email: [email protected]